New hope for blood cancer patients in Early-Stage trial
NCT ID NCT07387354
Summary
This study is testing a new combination of two drugs, pacritinib and azacitidine, for people with a type of blood and bone marrow cancer called myelodysplastic syndrome (MDS). The first part of the study will find the safest dose. The second part will see if this dose helps control the disease in about 25 participants. Researchers will also check how the treatment affects certain signals inside blood cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.